Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ARTV

Artiva Biotherapeutics Inc

Feb 06 • 04:00PM ET

4.03

+0.16 4.13 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN BMY AMGN MRNA PFE NVAX VRTX SAGE NTLA

| Held by: VTI VXF IWC DCOR DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.25	Insider Own	52.30%	Shs Outstand	24.54M	Perf Week	3.60%
Market Cap	98.92M	Forward P/E	-	EPS next Y	-3.36	Insider Trans	-0.47%	Shs Float	11.71M	Perf Month	-12.39%
Enterprise Value	-12.36M	PEG	-	EPS next Q	-0.84	Inst Own	53.53%	Short Float	2.43%	Perf Quarter	17.15%
Income	-79.19M	P/S	-	EPS this Y	41.14%	Inst Trans	-0.75%	Short Ratio	0.28	Perf Half Y	52.65%
Sales	0.00M	P/B	0.77	EPS next Y	1.66%	ROA	-42.29%	Short Interest	0.28M	Perf YTD	-6.06%
Book/sh	5.26	P/C	0.80	EPS next 5Y	24.02%	ROE	-47.96%	52W High	7.36 -45.24%	Perf Year	-17.42%
Cash/sh	5.01	P/FCF	-	EPS past 3/5Y	12.99% -64.01%	ROIC	-57.49%	52W Low	1.47 174.15%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-49.95% -	Gross Margin	-	Volatility	8.36% 8.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-17.10%	Oper. Margin	-	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.65	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	44.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.65	EPS Q/Q	-22.24%	SMA20	-9.82%	Beta	2.74	Target Price	17.00
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	-4.04%	Rel Volume	0.14	Prev Close	3.87
Employees	89	LT Debt/Eq	0.07	Earnings	Nov 12 BMO	SMA200	30.22%	Avg Volume	1.03M	Price	4.03
IPO	Jul 19, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-1.35% -	Trades		Volume	145,053	Change	4.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Resumed	H.C. Wainwright	Buy	$12
Dec-30-24	Initiated	H.C. Wainwright	Buy	$20
Aug-13-24	Initiated	Wedbush	Outperform	$18
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Needham	Buy	$23
Aug-13-24	Initiated	Jefferies	Buy	$21
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight	$23

Jan-21-26 08:00AM	Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL (GlobeNewswire)
Dec-14-25 06:05AM	Wedbush Predicts Up to ~600% Jump for These 2 Strong Buy Stocks (TipRanks)
Nov-12-25 07:20AM	Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease (GlobeNewswire) +10.86%
07:00AM	Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-25 04:05PM	Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK (GlobeNewswire) -9.59%
04:17PM	Loading…
Oct-30-25 04:17PM	Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire) -10.25% +5.84%
Oct-22-25 07:41AM	Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101) (Insider Monkey)
Oct-16-25 04:05PM	Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update (GlobeNewswire) -7.97% +116.97%
Aug-25-25 04:05PM	Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-06-25 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights (GlobeNewswire) -6.82% -8.01%
May-28-25 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.77%
May-13-25 04:05PM	Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire) -11.71%
May-08-25 08:00AM	Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights (GlobeNewswire)
Apr-28-25 04:35PM	Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-08-25 04:05PM	Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer (GlobeNewswire) -41.99%
04:05PM	Loading…
Mar-31-25 04:05PM	Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.06%
Mar-24-25 04:05PM	Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -8.43%
Feb-20-25 04:05PM	Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.72%
Jan-29-25 04:05PM	Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. (GlobeNewswire)
Nov-12-24 04:05PM	Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -10.48%
Nov-11-24 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) +7.82%
Sep-10-24 04:05PM	Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-29-24 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-18-24 07:08PM	Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering (GlobeNewswire)

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aslan Fred	President and CEO	Dec 15 '25	Sale	6.00	3,187	19,122	1,209,948	Dec 15 09:19 PM
FRED ASLAN	Director	Dec 15 '25	Proposed Sale	3.30	12,749	42,072		Dec 15 04:18 PM
Aslan Fred	President and CEO	Nov 17 '25	Sale	3.38	6,375	21,522	343,999	Nov 17 08:37 PM
FRED ASLAN	Director	Nov 17 '25	Proposed Sale	3.25	6,375	20,719		Nov 17 04:29 PM
Aslan Fred	President and CEO	Oct 17 '25	Sale	6.00	25,500	153,000	356,721	Oct 17 08:44 PM
FRED ASLAN	Director	Oct 17 '25	Proposed Sale	2.77	25,500	70,635		Oct 17 04:17 PM
Aslan Fred	President and CEO	Aug 15 '25	Sale	2.73	25,500	69,579	386,693	Aug 18 08:15 PM
FRED ASLAN	Director	Aug 15 '25	Proposed Sale	2.70	25,500	68,850		Aug 15 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTV

Artiva Biotherapeutics Inc

Upgrade your FINVIZ experience